CLINICAL TRIAL / NCT05918692

Key Inclusion Criteria: - Age ≥ 18 years. - Individuals with histologically or pathologically confirmed diagnosis of relapsed or refractory AML, ALL, or MPAL with documented FLT3 mutation, and/or Individuals with histologically or pathologically confirmed diagnosis of their malignancy with wild-type FLT3 (including those with MLL1-R and NPM1 mutations). - ECOG performance status of 0-2. - Adequate liver and renal function - Adhere to the CYP3A4 inhibitor concomitant therapy use requirements, as follows: - Arm A: Participants must not have received a moderate or strong CYP3A4 inhibitor for at least 7 days prior to enrollment and are not anticipated to require such agents in the near term (for at least 4 weeks). - Arm B: Participants must have received a necessary azole antifungal(s) that is a moderate or strong CYP3A4 inhibitor (excluding other moderate or strong CYP3A4 inhibitor[s]) for at least 7 days prior to enrollment and be able to continue such azole antifungal(s) while on BMF-500 treatment for at least 4 weeks. Key Exclusion Criteria: - Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension or arrhythmia, history of cerebrovascular accident including transient ischemic attack within 6 months prior to the first dose of the trial intervention. - WBC count >50,000/µL (uncontrollable with cytoreductive therapy). - Women who are pregnant or lactating or plan to become pregnant.